Seres Therapeutics Inc
Seres Therapeutics Inc logo
MCRB

Seres Therapeutics Inc (MCRB)

$6.234.59%

Market is closed
– opens on 8 PM, 07 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$5.9314
Day's Range
$6.56
$2.5
52-Week Range
$10.98
1 month return16.92%
3 month return20.93%
1 year return34.83%
5 year return33.3%

Company Information

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.
OrganizationSeres Therapeutics Inc
Employees333
CEOMr. Eric D. Shaff M.B.A.
IndustryHealth Technology

Analyst Recommendation

based on 9 analysts ratings

Buy
77%
Buy
11%
Hold
11%
Sell

Based on 9 Wall street analysts offering stock ratings for Seres Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 105.1%

Current

$6.27

Target

$12.86

Recommendation Trend

Based on 9 analyst

Current1M Ago3M Ago
Buy
7
12
12
Hold
1
1
1
Sell
1
1
1
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
864.0M
Book Value
$0.54
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.94
PEG Ratio
-0.11
Wall Street Target Price
12.86

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
13.14
Enterprise Value
731.4M
Enterprise Value/Revenue
50.64
Enterprise Value/Ebitda
-3.33

Technicals

Beta
2.79
50 Day MA
6.95
200 Day MA
5.64

Institutional Holdings

Flagship Ventures Management, Inc.

18.55%

FMR Inc

14.93%

Federated Hermes Inc

14.43%

HHG PLC

8.96%

Vanguard Group Inc

5.31%

BlackRock Inc

5.06%

Discover more

Frequently Asked Questions

What is Seres Therapeutics Inc share price today?

Can Indians buy Seres Therapeutics Inc shares?

How can I buy Seres Therapeutics Inc shares from India?

Can Fractional shares of Seres Therapeutics Inc be purchased?

What are the documents required to start investing in Seres Therapeutics Inc stocks?

What are today’s High and Low prices of Seres Therapeutics Inc?

What are today’s traded volumes of Seres Therapeutics Inc?

What is today’s market capitalisation of Seres Therapeutics Inc?

What is the 52 Week High and Low Range of Seres Therapeutics Inc?

How much percentage Seres Therapeutics Inc is down from its 52 Week High?

How much percentage Seres Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Seres Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Seres Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*